Accro Bioscience (Suzhou) Limited, trading as Accropeutics, is a clinical-stage biopharmaceutical company founded in 2017 with operations in Suzhou, China and New York. It develops small-molecule therapeutics against regulated cell death — necroptosis, pyroptosis and ferroptosis — targeting the cell-death-to-inflammation loop behind inflammatory, fibrotic, autoimmune and oncology disease. Its pipeline is led by AC-101, an oral selective RIPK2 inhibitor in Phase Ib for ulcerative colitis with FDA clearance for a Phase II multi-regional IBD study; AC-201, a TYK2/JAK1 pseudokinase inhibitor licensed to Fosun Pharma for Greater China as FXS5626; and AC-003, a RIPK1 inhibitor in Phase Ib for acute graft-versus-host disease with FDA Orphan Drug Designation. It closed a $50M Series C led by OrbiMed in May 2026. Accro Bioscience sells drug candidates, not software: it runs no developer program and publishes no API, SDK or machine-readable API contract.
Accro Bioscience is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Clinical Trials.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: accrobioscience
name: Accro Bioscience
description: 'Accro Bioscience (Suzhou) Limited, trading as Accropeutics, is a clinical-stage biopharmaceutical company founded
in 2017 with operations in Suzhou, China and New York. It develops small-molecule therapeutics against regulated cell death
— necroptosis, pyroptosis and ferroptosis — targeting the cell-death-to-inflammation loop behind inflammatory, fibrotic,
autoimmune and oncology disease. Its pipeline is led by AC-101, an oral selective RIPK2 inhibitor in Phase Ib for ulcerative
colitis with FDA clearance for a Phase II multi-regional IBD study; AC-201, a TYK2/JAK1 pseudokinase inhibitor licensed
to Fosun Pharma for Greater China as FXS5626; and AC-003, a RIPK1 inhibitor in Phase Ib for acute graft-versus-host disease
with FDA Orphan Drug Designation. It closed a $50M Series C led by OrbiMed in May 2026. Accro Bioscience sells drug candidates,
not software: it runs no developer program and publishes no API, SDK or machine-readable API contract.'
url: https://raw.githubusercontent.com/api-evangelist/accrobioscience/refs/heads/main/apis.yml
image: https://www.accropeutics.com/upload/2024-05/171677317462138100.svg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Clinical Trials
- Life Sciences
- Immunology
- inflammation
- Small Molecule
- Regulated Cell Death
tags_raw:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Clinical Trials
- Life Sciences
- Immunology
- Inflammation
- Small Molecule
- Regulated Cell Death
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/accrobioscience-domain-security.yml
- type: Website
url: https://www.accropeutics.com/
- type: About
url: https://www.accropeutics.com/about
- type: Newsroom
url: https://www.accropeutics.com/news
- type: Contact
url: https://www.accropeutics.com/contact
- type: Partners
url: https://www.accropeutics.com/partnerships
- type: Careers
url: https://www.accropeutics.com/join
- type: LinkedIn
url: https://www.linkedin.com/company/95295041/
- type: SecondaryMarket
url: https://equityzen.com/company/accrobioscience
x-enrichment:
date: '2026-09-06'
status: minimal
artifacts_added: 2
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: Accro Bioscience (Suzhou) Limited is a clinical-stage biopharmaceutical company whose product is a small-molecule
drug pipeline (AC-101, AC-201, AC-003), not software; its entire public surface is the accropeutics.com corporate site
— about, focus areas, pipeline, partnerships, news, join us, contact — with no developer, docs, portal or integration
link anywhere in the nav or footer, and the site does not even serve a /robots.txt or /sitemap.xml. Every REST/GraphQL/agent-card,
/llms.txt and /.well-known/ path probed on both www.accropeutics.com and accropeutics.com returns an identical 548-byte
hard 404, verified against a random control path returning the same body and byte count; api., dev., docs., developer.,
portal., data. and mcp..accropeutics.com do not resolve in DNS, and there is no GitHub organization and no npm or PyPI
package under either the Accro Bioscience or Accropeutics name.
evidence:
- url: https://www.accropeutics.com/
status: 200
- url: https://www.accropeutics.com/openapi.json
status: 404
- url: https://www.accropeutics.com/swagger.json
status: 404
- url: https://www.accropeutics.com/api-docs
status: 404
- url: https://www.accropeutics.com/graphql
status: 404
- url: https://www.accropeutics.com/developers
status: 404
- url: https://www.accropeutics.com/llms.txt
status: 404
- url: https://www.accropeutics.com/robots.txt
status: 404
- url: https://www.accropeutics.com/.well-known/agent-card.json
status: 404
- url: https://www.accropeutics.com/.well-known/agent.json
status: 404
- url: https://www.accropeutics.com/.well-known/api-catalog
status: 404
- url: https://accropeutics.com/.well-known/security.txt
status: 404
- url: https://www.accropeutics.com/zz-api-evangelist-control-7c1e
status: 404
- url: https://api.github.com/search/users?q=accro+bioscience
status: 200
checked: '2026-09-06'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.